Mecamylamine labels and packages: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Mecamylamine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==PACKAGE/LABEL PRINCIPAL DISPLAY PANEL== | |||
{| | |||
| [[image:meca2.jpg|400px|thumb]] | |||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | ||
Revision as of 14:58, 10 March 2014
| Mecamylamine |
|---|
| Mecamylamine tablet®, Vecamyl® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Mecamylamine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
 |
References
- ↑ "VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS]". Retrieved 10 March 2014.